OnKure Therapeutics (OKUR) to Release Quarterly Earnings on Thursday

OnKure Therapeutics (NASDAQ:OKUR - Get Free Report) will likely be announcing its earnings results before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($1.08) per share for the quarter.

OnKure Therapeutics (NASDAQ:OKUR - Get Free Report) last released its quarterly earnings results on Monday, March 10th. The company reported ($1.37) EPS for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.51). On average, analysts expect OnKure Therapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

OnKure Therapeutics Stock Performance

Shares of OKUR stock traded up $0.05 during trading hours on Friday, reaching $5.05. 19,042 shares of the company's stock were exchanged, compared to its average volume of 85,453. The stock has a market cap of $67.85 million, a PE ratio of -0.41 and a beta of 0.28. The firm has a fifty day moving average price of $5.44. OnKure Therapeutics has a 1 year low of $4.45 and a 1 year high of $20.00.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on OKUR shares. Leerink Partners began coverage on shares of OnKure Therapeutics in a research note on Thursday, December 5th. They set an "outperform" rating and a $33.00 price target on the stock. Leerink Partnrs upgraded OnKure Therapeutics to a "strong-buy" rating in a research note on Thursday, December 5th. HC Wainwright dropped their price target on OnKure Therapeutics from $40.00 to $34.00 and set a "buy" rating on the stock in a research note on Tuesday, March 18th. Finally, Oppenheimer reduced their price objective on OnKure Therapeutics from $35.00 to $30.00 and set an "outperform" rating for the company in a research note on Tuesday, March 11th. Three analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $32.33.

About OnKure Therapeutics

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.